Roflumilast ( DrugBank: Roflumilast )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
84	サルコイドーシス	1
97	潰瘍性大腸炎	1
206	脆弱Ｘ症候群	1
299	嚢胞性線維症	5

84. サルコイドーシス

臨床試験数 : 149 / 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01830959 (ClinicalTrials.gov)	April 2013	10/4/2013	Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)	Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)	Sarcoidosis	Drug: Roflumilast;Drug: Placebo	University of Cincinnati	The Cleveland Clinic;University of Pittsburgh;University of Illinois at Chicago;Henry Ford Health Sy ...	Active, not recruiting	18 Years	70 Years	Both	50	Phase 4	United States

First Previous1Next Last

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05684484 (ClinicalTrials.gov)	February 1, 2023	26/12/2022	Role of Roflumilast in Ulcerative Colitis	Clinical Study to Evaluate the Possible Efficacy and Safety of Roflumilastin Patients With Ulcerativ ...	Ulcerative Colitis	Drug: Roflumilast500 Ug ORAL TABLET [Daliresp];Drug: corticosteroids +immune suppressive +amino sali ...	Tanta University	NULL	Not yet recruiting	15 Years	80 Years	All	52	Phase 4	NULL

First Previous1Next Last

206. 脆弱Ｘ症候群

臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05418049 (ClinicalTrials.gov)	September 8, 2022	31/5/2022	Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge	Evaluating the Neurophysiologic and Clinical Effects of Single-Dose Baclofen, Roflumilast, Memantine ...	Fragile X Syndrome	Drug: Baclofen;Drug: Memantine;Drug: Roflumilast;Drug: Placebo	Children's Hospital Medical Center, Cincinnati	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Recruiting	18 Years	45 Years	All	45	Phase 2	United States

First Previous1Next Last

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04322929 (ClinicalTrials.gov)	November 12, 2020	24/3/2020	Roflumilast in Non-CF Bronchiectasis Study (2019)	Anti-inflammatory Effects of RoflumilastTreatment for 12 Weeks in Stable-state Non-cystic Fibrosis B ...	Non-cystic Fibrosis Bronchiectasis	Drug: Roflumilast Oral Tablet	The University of Hong Kong	NULL	Recruiting	18 Years	N/A	All	27	Phase 2	Hong Kong
2	NCT03988816 (ClinicalTrials.gov)	December 6, 2019	14/6/2019	Effect of Roflumilaston Quality of Life, Lung Function and Mucus Properties in Patients With Bronchi ...	Effect of Roflumilaston Quality of Life, Lung Function and Mucus Properties in Patients With Non-cys ...	Bronchiectasis Adult	Drug: Roflumilast;Drug: Placebo oral tablet	University of Sao Paulo General Hospital	FAPESP - Fundação de Apoio à Pesquisa do Estado de São Paulo	Recruiting	18 Years	N/A	All	30	Phase 2	Brazil
3	NCT04090294 (ClinicalTrials.gov)	October 1, 2019	21/8/2019	Assessment of Early Outcomes of Roflumilast in Patients With Non Cystic Fibrosis Bronchiectasis	Assessment of Early Outcomes of Roflumilast in Patients With Non Cystic Fibrosis Bronchiectasis	Bronchiectasis	Drug: Roflumilast	Assiut University	NULL	Not yet recruiting	18 Years	75 Years	All	35	Early Phase 1	NULL
4	NCT03428334 (ClinicalTrials.gov)	May 10, 2018	26/1/2018	Roflumilast in Non-CF Bronchiectasis Study	A 4-week Single-arm Study of Roflumilast in Stable-state Non-cystic Fibrosis Bronchiectasis	Non-cystic Fibrosis Bronchiectasis	Drug: Oral roflumilast	The University of Hong Kong	NULL	Completed	18 Years	N/A	All	20	Phase 2	Hong Kong
5	NCT04122547 (ClinicalTrials.gov)	January 2015	8/10/2019	Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis	Efficacy of Roflumilaston Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis: a Rando ...	Exacerbation Copd;Bronchiectasis;Lung Function Decreased	Drug: Roflumilast;Drug: Placebo	Prince of Songkla University	NULL	Completed	18 Years	80 Years	All	40	Phase 3	Thailand

First Previous1Next Last

先頭へ